This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (42)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Venous Thromboembolism  • Cardiovascular System  • Review  • Alert me on articles by topic  Social Bookmarking   What's this?

A Systematic Review

Wai Khoon Ho, MBBS, FRACP; Graeme J. Hankey, MD, FRACP, FRCP; Daniel J. Quinlan, MBBS; John W. Eikelboom, MBBS, MSc, FRACP

Arch Intern Med. 2006;166:729-736.

The 2 most common genetic polymorphisms that predispose to a first episode of venous thromboembolism (VTE) are factor V Leiden (FVL) and prothrombin G20210A. However, the effect of these polymorphisms on the risk of recurrent VTE is unclear. We performed a meta-analysis to obtain best estimates of the relative risk of recurrent VTE associated with these genetic polymorphisms. Electronic and manual searches were used to identify cohort studies of patients with a first episode of VTE that reported the incidence of objectively confirmed recurrence following discontinuation of anticoagulation among those with or without heterozygous FVL or prothrombin G20210A polymorphism. Thirteen reports fulfilled our criteria for inclusion. Pooled results from 10 studies involving 3104 patients with first-ever VTE revealed that FVL was present in 21.4% of patients (95% confidence interval [CI], 20%-23%) and associated with an increased odds of recurrent VTE of 1.41 (95% CI, 1.14-1.75; P = .08 for heterogeneity). Pooled results from 9 studies involving 2903 patients with first-ever VTE revealed that prothrombin G20210A was present in 9.7% of patients (95% CI, 9%-11%) and associated with an increased odds of recurrent VTE of 1.72 (95% CI, 1.27-2.31; P = .19). The estimated population-attributable risk of recurrence for FVL was 9.0% (95% CI, 4.5%-13.2%) and for prothrombin G20210A was 6.7% (95% CI, 3.4%-9.9%). Heterozygous FVL and prothrombin G20210A are each associated with a significantly increased risk of recurrent VTE after a first event, but the magnitude of the increase in risk is modest and by itself is unlikely to merit extended-duration anticoagulation. These data call into question the cost-effectiveness of routine testing for these common inherited thrombophilic polymorphisms among patients with a first episode of VTE.

Author Affiliations: Department of Haematology, Royal Perth Hospital and Centre for Clinical Research Excellence (Dr Ho), Stroke Unit, Royal Perth Hospital and School of Medicine and Pharmacology (Dr Hankey), University of Western Australia, Perth; Department of Radiology, King's College Hospital, London, England (Dr Quinlan); and Department of Medicine, McMaster University, Hamilton, Ontario (Dr Eikelboom).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Genetics and the general physician: insights, applications and future challenges
Knight
QJM 2009;102:757-772.
ABSTRACT | FULL TEXT  

Preventing recurrent venous thromboembolism
DTB 2009;47:38-40.
ABSTRACT | FULL TEXT  

Venous Thromboembolism: Risk Factors for Recurrence
Zhu et al.
Arterioscler. Thromb. Vasc. Bio. 2009;29:298-310.
ABSTRACT | FULL TEXT  

Motivating Factors for Physician Ordering of Factor V Leiden Genetic Tests
Hindorff et al.
Arch Intern Med 2009;169:68-74.
ABSTRACT | FULL TEXT  

Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial
Kearon et al.
Blood 2008;112:4432-4436.
ABSTRACT | FULL TEXT  

Systematic Review: D-Dimer to Predict Recurrent Disease after Stopping Anticoagulant Therapy for Unprovoked Venous Thromboembolism
Verhovsek et al.
ANN INTERN MED 2008;149:481-490.
ABSTRACT | FULL TEXT  

Impact of Inherited Thrombophilia on Venous Thromboembolism in Children: A Systematic Review and Meta-Analysis of Observational Studies
Young et al.
Circulation 2008;118:1373-1382.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Kearon et al.
Chest 2008;133:454S-545S.
ABSTRACT | FULL TEXT  

A Clinical Perspective of Venous Thromboembolism
Moll
Arterioscler. Thromb. Vasc. Bio. 2008;28:373-379.
FULL TEXT  

Thrombophilia in Children: Who to Test, How, When, and Why?
Raffini
ASH Education Book 2008;2008:228-235.
ABSTRACT | FULL TEXT  

Thrombophilia States and Markers of Coagulation Activation in the Prediction of Pediatric Venous Thromboembolic Outcomes: A Comparative Analysis with Respect to Adult Evidence
Goldenberg
ASH Education Book 2008;2008:236-244.
ABSTRACT | FULL TEXT  

Risk of recurrence after a first venous thromboembolic event in young women
Laczkovics et al.
haematol 2007;92:1201-1207.
ABSTRACT | FULL TEXT  

The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies
Marchiori et al.
haematol 2007;92:1107-1114.
ABSTRACT | FULL TEXT  

Thrombophilia: Common Questions on Laboratory Assessment and Management
Heit
ASH Education Book 2007;2007:127-135.
ABSTRACT | FULL TEXT  

Hemostasis and thrombosis
Crowther and Abshire
ASH-SAP 2007;2007:361-407.
FULL TEXT  

Evidently...
Lehman
Evid. Based Med. 2006;11:102-102.
FULL TEXT  

Other articles noted
Evid. Based Med. 2006;11:127-128.
FULL TEXT  

Thrombosis in Infants and Children
Schneppenheim and Greiner
ASH Education Book 2006;2006:86-96.
ABSTRACT | FULL TEXT